Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequencing Pembrolizumab and Chemotherapy in NSCLC
NCT02591615Phase 2Completed
- Sponsor
- Alliance Foundation Trials
- Start
- Mar 2016
- Primary completion
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Alliance Foundation Trials. Started Mar 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02591615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02591615.